Novo Nordisk says high-dose semaglutide trial shows 20.7% weight loss
Novo Nordisk said on Friday that a late-stage trial with 7.2 milligram (mg) of semaglutide, a high-dose version of the active ingredient used in its blockbuster obesity drug Wegovy, helped overweight patients cut their weight by 20.7%.